4SC-202 treatment was compared to the vehicle or the broad spectrum HDAC inhibitor Vorinostat, which is used clinically to treat cutaneous T-cell lymphoma. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.